Literature DB >> 6491661

Formation and clearance of norepinephrine glycol metabolites in mouse brain.

P P Li, J J Warsh, D D Godse.   

Abstract

To determine the degree of conversion of 3,4-dihydroxyphenylethyleneglycol (DHPG) to 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) and the amount of DHPG eliminated unchanged from the brain, we have examined the kinetics of formation and disappearance of mouse brain MHPG and DHPG following clorgyline (10 mg/kg, i.p.) and/or tropolone (75 mg/kg, i.p.) treatment. During the first 10 min after tropolone, brain DHPG levels accumulated linearly at a rate of 1,300 pmol/g/h, whereas MHPG disappeared exponentially at a rate of 411 pmol/g/h. Following clorgyline administration, brain DHPG declined exponentially at a rate of 1,240 pmol/g/h. In contrast, the elimination of MHPG became a first-order process only when catechol-O-methyltransferase (COMT) was also inhibited in addition to monoamine oxidase. Thus, combined clorgyline and tropolone treatment resulted in an exponential decline of MHPG levels at a rate of 524 pmol/g/h, whereas DHPG levels were slightly but significantly elevated compared to control values. When the animals were treated with pargyline (75 mg/kg, i.p.) in combination with clorgyline and tropolone, brain DHPG and MHPG disappeared at rates of 40 and 660 pmol/g/h, respectively. The above observations suggest that mouse brain DHPG is cleared primarily through O-methylation with minimal direct elimination from brain. Assuming the disposition and clearance of norepinephrine metabolites are similar in mouse and human brain, peripherally measured DHPG in humans is likely derived principally from extracerebral sources and reflects peripheral sympathetic function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491661     DOI: 10.1111/j.1471-4159.1984.tb05404.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Biopsychosocial influence on shoulder pain: Rationale and protocol for a pre-clinical trial.

Authors:  Steven Z George; Roland Staud; Paul A Borsa; Samuel S Wu; Margaret R Wallace; Warren H Greenfield; Lauren N Mackie; Roger B Fillingim
Journal:  Contemp Clin Trials       Date:  2017-03-14       Impact factor: 2.226

2.  Genetic influences on the dynamics of pain and affect in fibromyalgia.

Authors:  Patrick H Finan; Alex J Zautra; Mary C Davis; Kathryn Lemery-Chalfant; Jonathan Covault; Howard Tennen
Journal:  Health Psychol       Date:  2010-03       Impact factor: 4.267

3.  Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder.

Authors:  M Karayiorgou; M Altemus; B L Galke; D Goldman; D L Murphy; J Ott; J A Gogos
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

4.  Distribution of 3,4-dihydroxyphenylacetic acid (DOPAC) and 3,4-dihydroxyphenylglycol (DOPEG) in microdissected brain structures and the pituitary gland: metabolite changes in the median eminence in response to hyperprolactinemia and suckling.

Authors:  J I Mechanick; I R Cohen-Becker; K A Gregerson; M Selmanoff
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

5.  Effects of naloxone-precipitated withdrawal after a single dose of morphine on catecholamine concentrations in guinea-pig brain.

Authors:  P J Brent; L A Chahl
Journal:  Neurochem Res       Date:  1991-05       Impact factor: 3.996

6.  Changes induced by sodium cromoglycate in brain catecholamine turnover in morphine dependent and abstinent mice.

Authors:  O San-Martín-Clark; B Cuéllar; J De Alba; J C Leza; P Lorenzo
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

7.  Further characterization of brain 3,4-dihydroxyphenylethyleneglycol (DHPG) formation: dependence on noradrenergic activity and site of formation.

Authors:  P P Li; J J Warsh; D D Godse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.